Unspecified immune checkpoint molecule

The term 'Unspecified immune checkpoint molecule' refers to a generic category of proteins that serve as regulators of the immune system, maintaining self-tolerance and modulating the duration and intensity of immune responses. These molecules, which include well-known targets such as Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), are often exploited by tumors to evade immune surveillance [1]. In a clinical context, drugs targeting these molecules—primarily checkpoint inhibitors—aim to restore or enhance the body's natural anti-tumor immune response [1][3]. Because this entry does not specify a particular molecular entity, it represents a broad therapeutic class rather than a single drug target. The use of therapies affecting these pathways is frequently associated with immune-related adverse events (irAEs), which occur when the loss of checkpoint-mediated regulation leads to unintended immune attacks on healthy tissues [2]. [1] Pardoll, D. M. (2012). Nature Reviews Cancer, 12(4), 252-264. [2] Postow, M. A., et al. (2018). New England Journal of Medicine, 378(2), 158-168. [3] National Cancer Institute (NCI). Immune Checkpoint Inhibitors. cancer.gov.

Other names

Immune checkpointImmune checkpoint proteinImmune checkpoint receptorImmunomodulatory checkpoint

Immune checkpoint molecules are targeted by therapeutic agents, such as monoclonal antibodies, to either block inhibitory signals (checkpoint inhibitors) or stimulate activating signals (checkpoint agonists) to modulate the immune system's response to pathological conditions.